Skip to content
Biodatica
Start free

MiNDERA Corp

VISTA, CA

OncologyFormed
Compare Sign in to watch

What changed

$19M raise filed (Form D/A)

10mo agoRaise filed (Form D)Sep 15, 2025Source filing (opens the source filing in a new tab)

Momentum

57no change

Momentum 57 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

~100months

The last disclosed raise still models out past a year.

Stage

Formed

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

20 pre-ticker oncology companies at Formed

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D/A · $19M

    Sep 15, 2025

    MiNDERA Corp · private raise, self-reported by the issuer

    SEC EDGAR · 0001629564-25-000002 (opens the source filing in a new tab)

  2. Grant

    R01 · $500k · non-dilutive

    Jul 18, 2024

    UNIVERSITY OF MARYLAND BALTIMORE · PI WOLFF, STEFFEN · NIMH · award ends Mar 31, 2029 · A circuit mechanism for the interactions between distinct learning systems

    NIH RePORTER · NIH RePORTER 11141200 (opens the source filing in a new tab)

  3. Grant

    R35 · $581k · non-dilutive

    Apr 1, 2024

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · NIGMS · award ends Mar 31, 2029 · Proteostasis signaling in cell cycle control

    NIH RePORTER · NIH RePORTER 11055986 (opens the source filing in a new tab)

  4. Grant

    R01 · $622k · non-dilutive

    Feb 1, 2024

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI PURVIS, JEREMY · NCI · award ends Jan 31, 2029 · Cell cycle paths as a framework for understanding drug resistance in tumor cell subpopulations

    NIH RePORTER · NIH RePORTER 11012299 (opens the source filing in a new tab)

  5. Grant

    P20 · $307k · non-dilutive

    Jan 1, 2024

    UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI COOK, JASON RHEDE · NIGMS · award ends Dec 31, 2028 · Regulation of Cardiovascular Physiology in Marfan Syndrome

    NIH RePORTER · NIH RePORTER 11004716 (opens the source filing in a new tab)

  6. Grant

    R35 · $575k · non-dilutive

    Jul 1, 2021

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN · NIGMS · award ends Jun 30, 2027 · Cell Cycle Dynamics that Ensure Genome Maintenance

    NIH RePORTER · NIH RePORTER 11126689 (opens the source filing in a new tab)

  7. Grant

    R01 · $615k · non-dilutive

    May 1, 2021

    UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOSLEHI, JAVID J · NHLBI · award ends Apr 30, 2026 · Long-Term Cardiovascular Sequelae of Cancer Immunotherapies

    NIH RePORTER · NIH RePORTER 11138699 (opens the source filing in a new tab)

  8. Grant

    T32 · $534k · non-dilutive

    Jul 1, 2020

    UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · NIGMS · award ends Jun 30, 2030 · Pharmacological Sciences Training Program

    NIH RePORTER · NIH RePORTER 11016572 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources